Revvity (RVTY) Projected to Post Earnings on Tuesday

Revvity (NYSE:RVTY) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $1.21 per share and revenue of $702.9570 million for the quarter. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 7:30 AM ET.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The company had revenue of $711.12 million during the quarter, compared to analysts’ expectations of $704.07 million. During the same period in the prior year, the business earned $1.01 EPS. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Revvity Stock Down 0.7%

NYSE RVTY opened at $112.79 on Friday. The business’s fifty day simple moving average is $106.51 and its 200-day simple moving average is $99.91. The company has a quick ratio of 1.41, a current ratio of 1.72 and a debt-to-equity ratio of 0.37. The firm has a market cap of $12.58 billion, a PE ratio of 53.96, a P/E/G ratio of 2.21 and a beta of 1.09. Revvity has a 52 week low of $81.22 and a 52 week high of $118.30.

Analysts Set New Price Targets

RVTY has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Revvity from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. JPMorgan Chase & Co. dropped their target price on Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Zacks Research lowered Revvity from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Evercore reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Revvity in a research report on Monday, July 6th. Finally, Wolfe Research assumed coverage on Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Three equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $108.36.

Hedge Funds Weigh In On Revvity

Institutional investors and hedge funds have recently modified their holdings of the company. Banco Bilbao Vizcaya Argentaria S.A. lifted its holdings in Revvity by 42.7% during the 3rd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 5,551 shares of the company’s stock worth $482,000 after buying an additional 1,661 shares during the last quarter. Brown Brothers Harriman & Co. boosted its position in shares of Revvity by 61.1% during the 4th quarter. Brown Brothers Harriman & Co. now owns 4,098 shares of the company’s stock worth $396,000 after acquiring an additional 1,554 shares in the last quarter. Quantitative Investment Management LLC increased its holdings in shares of Revvity by 19.4% in the 4th quarter. Quantitative Investment Management LLC now owns 4,014 shares of the company’s stock valued at $388,000 after acquiring an additional 653 shares during the last quarter. Virtu Financial LLC purchased a new stake in Revvity during the fourth quarter worth approximately $384,000. Finally, Baird Financial Group Inc. boosted its holdings in Revvity by 17.2% in the second quarter. Baird Financial Group Inc. now owns 3,333 shares of the company’s stock valued at $322,000 after purchasing an additional 488 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.